<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Targeted phototherapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Targeted phototherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Targeted phototherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven R Feldman, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Craig A Elmets, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 16, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H951692249"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Targeted phototherapy is the localized delivery of ultraviolet (UV) light to affected areas of skin using laser or nonlaser devices [<a href="#rid1">1</a>]. This treatment modality may be useful in some patients with psoriasis, vitiligo, and other inflammatory or lymphoproliferative skin conditions (<a class="graphic graphic_table graphicRef104201" href="/d/graphic/104201.html" rel="external">table 1</a>) involving a limited area of the body (&lt;10 percent of the body surface area) or difficult-to-treat anatomical areas [<a href="#rid2">2</a>].</p><p>This topic will discuss the mechanism of action, clinical indications, treatment protocols, and side effects of targeted phototherapy. Psoralen plus ultraviolet A (PUVA), ultraviolet B (UVB), and ultraviolet A1 (UVA1) phototherapy are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/91676.html" rel="external">"UVA1 phototherapy"</a>.)</p><p></p><p class="headingAnchor" id="H951692255"><span class="h1">PRINCIPLES AND MECHANISMS</span><span class="headingEndMark"> — </span>Targeted phototherapy can be performed with either laser or nonlaser devices that emit a spot of ultraviolet (UV) light, typically a few square centimeters. Both laser and nonlaser devices can deliver UV radiation (wavelength range 193 to 380 nm (<a class="graphic graphic_figure graphicRef70045" href="/d/graphic/70045.html" rel="external">figure 1</a>)) that is absorbed in the epidermis and superficial dermis by skin chromophores.</p><p>The principal skin chromophore is nuclear deoxyribonucleic acid (DNA). The absorption of ultraviolet B (UVB; 290 to 320 nm) by nucleotides leads to the formation of cyclobutane pyrimidine dimers and pyrimidine (6-4)-photoproducts, which are then either repaired or marked for cell cycle arrest and apoptosis via the p53 tumor suppressor gene system [<a href="#rid3">3</a>]. UVB also acts on cytoplasm and cell membrane components (including cell surface receptors, kinases, phosphatases, and transcription factors) and induces the release of a variety of proinflammatory and immunomodulatory cytokines from keratinocytes and T cells [<a href="#rid4">4</a>].</p><p>Decreased cell proliferation, immunosuppression, and T cell apoptosis may contribute to the UVB-mediated suppression of disease activity in inflammatory and lymphoproliferative skin disorders, such as psoriasis and mycosis fungoides [<a href="#rid5">5-7</a>]. In vitiligo, UVB promotes the proliferation, differentiation, and migration of melanocytes [<a href="#rid8">8</a>]. In cutaneous mastocytosis (urticaria pigmentosa), UVB radiation reduces the release of histamine from basophils and mast cells, resulting in decreased itch and fewer urticarial lesions [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H951692261"><span class="h1">DEVICES FOR TARGETED PHOTOTHERAPY</span><span class="headingEndMark"> — </span>The most common lasers used for targeted phototherapy in clinicians' offices are the excimer lasers, which operate in the ultraviolet (UV) wavelength range between 193 and 351 nm. These lasers use an active medium composed of excited dimers, which are a combination of a noble gas (eg, argon, krypton, or xenon) and a reactive halogen gas (eg, fluorine or chlorine) [<a href="#rid11">11</a>]. The 308 nm xenon-chloride laser is most commonly used to treat dermatologic conditions. Although effective, laser devices tend to be bulky and expensive. (See  <a class="medical medical_review" href="/d/html/2883.html" rel="external">"Basic principles of medical lasers"</a> and  <a class="medical medical_review" href="/d/html/13648.html" rel="external">"Principles of laser and intense pulsed light for cutaneous lesions"</a>.)</p><p>Nonlaser devices can also be used to deliver localized UV to targeted lesions. They may use high-pressure burners, fluorescent bulbs, or other approaches to emit UV light and may be delivered to the skin either directly from the bulb or via fiber-optic cable systems [<a href="#rid12">12</a>]. Nonlaser excimer lamps are generally smaller, less costly, and require less maintenance than lasers [<a href="#rid12">12</a>]; some are available that can be used by patients at home and may be as effective as in-office treatment [<a href="#rid13">13,14</a>]. A nonlaser device can sometimes be filtered to provide either ultraviolet A (UVA; 330 to 380 nm) or ultraviolet B (UVB; 290 to 330 nm), which cannot be done with excimer lasers [<a href="#rid11">11,15,16</a>]. Monochromatic excimer nonlaser devices have been developed but are not yet approved by the US Food and Drug Administration for use in the United States.</p><p class="headingAnchor" id="H951692267"><span class="h1">CLINICAL INDICATIONS</span><span class="headingEndMark"> — </span>Most common indications for targeted ultraviolet (UV) therapy include:</p><p class="bulletIndent1"><span class="glyph">●</span>Localized forms of moderate to severe psoriasis that are unresponsive to topical therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Vitiligo</p><p class="bulletIndent1"><span class="glyph">●</span>Localized severe atopic dermatitis</p><p class="bulletIndent1"><span class="glyph">●</span>Alopecia areata [<a href="#rid17">17</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphoproliferative skin disorders [<a href="#rid2">2</a>]</p><p></p><p>Localized phototherapy is useful for difficult-to-treat areas (scalp, palms, and soles) in patients with psoriasis [<a href="#rid18">18</a>]. In patients with vitiligo, perifollicular pigmentation on baseline dermoscopic examination may be a marker for better response to targeted phototherapy [<a href="#rid19">19</a>]. Additional indications are listed in the table (<a class="graphic graphic_table graphicRef104201" href="/d/graphic/104201.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H951692273"><span class="h1">DOSING AND TREATMENT REGIMENS</span><span class="headingEndMark"> — </span>There are no widely accepted, disease-specific protocols for targeted phototherapy, due to lack of standardization among devices and limited evidence from high-quality studies. Only a few small studies have assessed the excimer laser dose-response relationship in psoriasis [<a href="#rid20">20</a>].</p><p>One approach supported by expert consensus involves determining the minimal erythema dose (MED) on normal skin prior to initial treatment. The MED is the lowest effective ultraviolet (UV) radiation dose producing erythema or "sunburn" of the skin within a few hours [<a href="#rid21">21</a>]. A dose of two to four MED can be given as the initial treatment. The dose can be increased or reduced during the course of treatment based upon response to therapy and side effects [<a href="#rid22">22</a>].</p><p>Another approach involves following the directions of the device's manufacturer for dosing. An example of protocol for a specific laser for psoriasis treatment is shown in the table (<a class="graphic graphic_table graphicRef104164" href="/d/graphic/104164.html" rel="external">table 2</a>).</p><p>Generally accepted treatment frequency is two to three treatment sessions per week, for a total of 10 to 20 treatments, or until the lesion is cleared [<a href="#rid12">12</a>]. Treatments should be given at least 48 hours apart [<a href="#rid23">23</a>]. For psoriasis, limited data show an average remission time of three to five months [<a href="#rid20">20</a>].</p><p>One small trial suggested that while both were effective, localized 308 nm excimer light may be more effective for vitiligo than targeted 311 nm narrowband ultraviolet B (NBUVB) [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H951692279"><span class="h1">COMBINATION THERAPIES</span><span class="headingEndMark"> — </span>Both topical and systemic agents can be used in conjunction with targeted phototherapy with the goal of improving efficacy and reducing the radiation dose. Evidence supporting the combination of targeted phototherapy with topical or systemic agents is mainly derived from a few studies of targeted and nontargeted narrowband ultraviolet B (NBUVB) phototherapy for the treatment of psoriasis and vitiligo:</p><p class="bulletIndent1"><span class="glyph">●</span>In a small study, the combination of targeted narrowband phototherapy with topical <a class="drug drug_general" data-topicid="9181" href="/d/drug information/9181.html" rel="external">calcipotriol</a> was more effective than phototherapy alone or phototherapy in combination with topical psoralen gel for the treatment of localized plaque psoriasis (Psoriasis Area and Severity Index [PASI] improvement after 30 treatments was 67, 34, and 30 percent, respectively) [<a href="#rid25">25</a>]. A meta-analysis of five small, randomized trials (182 patients) confirmed that topical calcipotriene improves the efficacy of targeted phototherapy of psoriasis (mean difference of the PASI percentage change between the combined therapy versus the targeted phototherapy alone -23, 95% CI -37 to -8) [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The combination of targeted phototherapy with biologics has not been well studied. In a small, retrospective study of 29 patients, the combination of biologics with 311 nm ultraviolet B (UVB) phototherapy was associated with a more rapid reduction in PASI compared with biologics alone [<a href="#rid27">27</a>]. None of the patients developed nonmelanoma skin cancer or melanoma over a median follow-up period of 234 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of two left-right intraindividual comparison studies comparing topical 0.1% <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> plus 308 nm xenon-chloride excimer laser with placebo plus laser for the treatment of vitiligo demonstrated that patches treated with the combination of topical tacrolimus plus laser were more likely to achieve 75 percent repigmentation than those treated with laser alone (RR 3.15; 95% CI 1.46-6.76) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaseline and other emollients can increase ultraviolet (UV) penetration by altering the optical properties of the stratum corneum [<a href="#rid29">29</a>]. Although evidence-based data are scant, some experts suggest applying a thin petrolatum layer just prior to UV treatment.</p><p></p><p class="headingAnchor" id="H951692285"><span class="h1">TARGETED VERSUS FULL-BODY PHOTOTHERAPY</span></p><p class="headingAnchor" id="H252290073"><span class="h2">Advantages</span><span class="headingEndMark"> — </span>Advantages of targeted phototherapy include less toxicity to normal skin, fewer treatments, and a lower cumulative ultraviolet (UV) dose compared with whole-body phototherapy [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Targeted therapy delivers a higher amount of radiation in a shorter period of time only to the individual lesions, avoiding unnecessary exposure to UV of the unaffected skin. This minimizes short- and long-term adverse effects of UV radiation exposure, such as sunburn and skin cancer. If burns do occur, they tend to be better tolerated, since they are limited to the lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because diseased skin often tolerates larger UV doses than normal skin, the initial treatments can use higher UV doses, resulting in a lower number of treatment sessions needed to achieve a response. Treatment duration may also be shorter with targeted phototherapy, unless very large areas are treated, and visits for treatment can be less frequent [<a href="#rid31">31</a>]. Moreover, refractory skin lesions not treated adequately with full-body phototherapy may respond to a more powerful, directed radiation treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Targeted phototherapy is particularly useful to treat difficult-to-treat anatomical locations. Lesions of the scalp, nose, genitals, oral mucosa, and ears are more easily and conveniently treated with targeted phototherapy [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Targeted phototherapy devices are available for home use. Patient-reported benefits include less time away from work, better compliance, and improved quality of life [<a href="#rid13">13,14</a>].</p><p></p><p class="headingAnchor" id="H252290079"><span class="h2">Disadvantages</span><span class="headingEndMark"> — </span>Targeted therapy is not generally used for lesions affecting greater than 10 percent of the body surface area. More extensive disease is more easily and conveniently treated with conventional broadband or narrowband ultraviolet B (NBUVB) treatments.</p><p>Targeted phototherapy is not widely available and is more expensive than conventional phototherapy, due to the higher cost of the machines for targeted phototherapy compared with the equipment used for full-body ultraviolet B (UVB) treatment.</p><p class="headingAnchor" id="H951692291"><span class="h1">SAFETY MEASURES</span><span class="headingEndMark"> — </span>Safety measures and contraindications should be reviewed with the patient prior to initiating treatment with targeted phototherapy. Safety measures can include:</p><p class="bulletIndent1"><span class="glyph">●</span>Protecting the skin surrounding the treated area by using a sunscreen with a sun protection factor (SPF) of 50+ or a physical barrier</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Using topical emollients and moisturizers for treated erythematous, dry, or blistering areas</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding additional sun exposure to treated areas</p><p></p><p class="headingAnchor" id="H951692297"><span class="h1">SHORT- AND LONG-TERM ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Short-term adverse effects of targeted phototherapy include localized erythema, burning, skin dryness and flaking, pruritus, and blistering, usually with higher doses. Hyperpigmentation of the treated areas may occur [<a href="#rid32">32</a>].</p><p>Long-term adverse effects of targeted phototherapy have not been extensively studied. They are theoretical and may include localized photoaging and possibly photocarcinogenesis. However, the risk of long-term adverse effects is expected to be smaller than with nontargeted phototherapy because a much smaller skin area is exposed to ultraviolet (UV) light when using a targeted approach.</p><p class="headingAnchor" id="H951692303"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Absolute contraindications for targeted phototherapy are:</p><p class="bulletIndent1"><span class="glyph">●</span>Xeroderma pigmentosum</p><p class="bulletIndent1"><span class="glyph">●</span>Lupus erythematosus</p><p class="bulletIndent1"><span class="glyph">●</span>Photosensitivity disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Nevoid basal cell carcinoma syndrome (Gorlin syndrome)</p><p></p><p>Relative contraindications to targeted ultraviolet B (UVB) therapy include:</p><p class="bulletIndent1"><span class="glyph">●</span>History of melanoma</p><p class="bulletIndent1"><span class="glyph">●</span>History of nonmelanoma skin cancer</p><p class="bulletIndent1"><span class="glyph">●</span>History of treatment with arsenic or ionizing radiation because of the increased risk for skin cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppression (eg, in organ transplant patients)</p><p></p><p class="headingAnchor" id="H951692309"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Principles and mechanisms</strong> – Targeted phototherapy is the localized delivery of ultraviolet (UV) light to affected skin with either laser or nonlaser devices that emit a spot of UV light, typically a few square centimeters, in one area. The 308 nm xenon-chloride laser is most commonly used to treat skin conditions. (See <a class="local">'Principles and mechanisms'</a> above and <a class="local">'Devices for targeted phototherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Indications of targeted phototherapy include inflammatory and lymphoproliferative skin conditions (<a class="graphic graphic_table graphicRef104201" href="/d/graphic/104201.html" rel="external">table 1</a>) involving a limited area of the body or difficult-to-treat areas. (See <a class="local">'Clinical indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and regimens</strong> – There are no widely accepted protocols for targeted phototherapy. Initial treatment can be based on minimal erythema dose (MED) testing. Subsequent treatments are based upon clinical response and side effects, for a total of 10 treatments or until lesions clear. (See <a class="local">'Dosing and treatment regimens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages of targeted phototherapy</strong> – Advantages of targeted phototherapy include less toxicity, fewer treatments, and a lower cumulative UV dose, compared with whole-body phototherapy. Since targeted phototherapy is only delivered to diseased skin, higher doses can be used, resulting in more rapid clearing with fewer treatment sessions. Targeted phototherapy devices are available for home use. Patient-reported benefits include less time away from work, better compliance, and improved quality of life. (See <a class="local">'Targeted versus full-body phototherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety measures</strong> – During targeted phototherapy, the skin surrounding the treated area can be protected by using a sunscreen with a sun protection factor (SPF) of 50+ or a physical barrier. Patients should avoid additional sun exposure to treated areas. (See <a class="local">'Safety measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Short-term adverse effects of targeted phototherapy include localized erythema, burning, pruritus, and blistering. Long-term adverse effects have not been extensively studied. They may include localized photoaging and photocarcinogenesis. (See <a class="local">'Short- and long-term adverse effects'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Aubin F, Vigan M, Puzenat E, et al. Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses. Br J Dermatol 2005; 152:99.</a></li><li><a class="nounderline abstract_t">Mehraban S, Feily A. 308nm excimer laser in dermatology. J Lasers Med Sci 2014; 5:8.</a></li><li class="breakAll">Garmyn M, Yarosh DB. The molecular and genetic effects of ultraviolet radiation exposure on skin cells. In: Photodermatology, Lim HW, Honigsmann H, Hawk JL (Eds), Informa Healthcare USA, Inc, 2007. p.41.</li><li><a class="nounderline abstract_t">Weichenthal M, Schwarz T. Phototherapy: how does UV work? Photodermatol Photoimmunol Photomed 2005; 21:260.</a></li><li><a class="nounderline abstract_t">Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007; 13:242.</a></li><li><a class="nounderline abstract_t">Novák Z, Bónis B, Baltás E, et al. Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B 2002; 67:32.</a></li><li><a class="nounderline abstract_t">Bianchi B, Campolmi P, Mavilia L, et al. Monochromatic excimer light (308 nm): an immunohistochemical study of cutaneous T cells and apoptosis-related molecules in psoriasis. J Eur Acad Dermatol Venereol 2003; 17:408.</a></li><li><a class="nounderline abstract_t">Goldstein NB, Koster MI, Hoaglin LG, et al. Narrow Band Ultraviolet B Treatment for Human Vitiligo Is Associated with Proliferation, Migration, and Differentiation of Melanocyte Precursors. J Invest Dermatol 2015; 135:2068.</a></li><li><a class="nounderline abstract_t">Metz M, Ständer S. Chronic pruritus--pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 2010; 24:1249.</a></li><li><a class="nounderline abstract_t">Rivard J, Lim HW. Ultraviolet phototherapy for pruritus. Dermatol Ther 2005; 18:344.</a></li><li><a class="nounderline abstract_t">Hamzavi I, Lui H. Using light in dermatology: an update on lasers, ultraviolet phototherapy, and photodynamic therapy. Dermatol Clin 2005; 23:199.</a></li><li><a class="nounderline abstract_t">Buckland M, Smith JS, Hill D, Feldman SR. A review of localized office and home devices in the treatment of psoriasis. Journal of Psoriasis and Psoriatic Arthritis 2016; 2:22.</a></li><li><a class="nounderline abstract_t">Nolan BV, Yentzer BA, Feldman SR. A review of home phototherapy for psoriasis. Dermatol Online J 2010; 16:1.</a></li><li><a class="nounderline abstract_t">Tien Guan ST, Theng C, Chang A. Randomized, parallel group trial comparing home-based phototherapy with institution-based 308 excimer lamp for the treatment of focal vitiligo vulgaris. J Am Acad Dermatol 2015; 72:733.</a></li><li><a class="nounderline abstract_t">Simon JC, Pfieger D, Schöpf E. Recent advances in phototherapy. Eur J Dermatol 2000; 10:642.</a></li><li><a class="nounderline abstract_t">Chimento SM, Newland M, Ricotti C, et al. A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo. J Drugs Dermatol 2008; 7:258.</a></li><li><a class="nounderline abstract_t">McMichael AJ. Excimer laser: a module of the alopecia areata common protocol. J Investig Dermatol Symp Proc 2013; 16:S77.</a></li><li><a class="nounderline abstract_t">Al-Mutairi N, Al-Haddad A. Targeted phototherapy using 308 nm Xecl monochromatic excimer laser for psoriasis at difficult to treat sites. Lasers Med Sci 2013; 28:1119.</a></li><li><a class="nounderline abstract_t">Errichetti E, Zelin E, Pinzani C, et al. Dermoscopic and Clinical Response Predictor Factors in Nonsegmental Vitiligo Treated with Narrowband Ultraviolet B Phototherapy: A Prospective Observational Study. Dermatol Ther (Heidelb) 2020; 10:1089.</a></li><li><a class="nounderline abstract_t">Asawanonda P, Anderson RR, Chang Y, Taylor CR. 308-nm excimer laser for the treatment of psoriasis: a dose-response study. Arch Dermatol 2000; 136:619.</a></li><li><a class="nounderline abstract_t">Heckman CJ, Chandler R, Kloss JD, et al. Minimal Erythema Dose (MED) testing. J Vis Exp 2013; :e50175.</a></li><li><a class="nounderline abstract_t">Mudigonda T, Dabade TS, Feldman SR. A review of protocols for 308 nm excimer laser phototherapy in psoriasis. J Drugs Dermatol 2012; 11:92.</a></li><li><a class="nounderline abstract_t">Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62:114.</a></li><li><a class="nounderline abstract_t">Poolsuwan P, Churee C, Pattamadilok B. Comparative efficacy between localized 308-nm excimer light and targeted 311-nm narrowband ultraviolet B phototherapy in vitiligo: A randomized, single-blind comparison study. Photodermatol Photoimmunol Photomed 2021; 37:123.</a></li><li><a class="nounderline abstract_t">Ozkan I, Köse O, Ozmen I, Arca E. Efficacy and safety of non-laser, targeted UVB phototherapy alone and in combination with psoralen gel or calcipotriol ointment in the treatment of localized, chronic, plaque-type psoriasis. Int J Dermatol 2012; 51:609.</a></li><li><a class="nounderline abstract_t">Gu X, Shen M, Zhao S, Chen X. Combination of targeted UVB phototherapy and calcipotriene versus targeted UVB alone in psoriasis: systematic review and meta-analysis of randomized controlled trials. J Dermatolog Treat 2022; 33:100.</a></li><li><a class="nounderline abstract_t">Inzinger M, Legat FJ, Hofer A, et al. Short- to intermediate-term follow-up in patients treated with the combination of 311-nm ultraviolet B phototherapy and biological agents. Br J Dermatol 2014; 171:915.</a></li><li><a class="nounderline abstract_t">Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev 2015; :CD003263.</a></li><li><a class="nounderline abstract_t">Lebwohl M, Martinez J, Weber P, DeLuca R. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol 1995; 32:469.</a></li><li><a class="nounderline abstract_t">Lapolla W, Yentzer BA, Bagel J, et al. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol 2011; 64:936.</a></li><li><a class="nounderline abstract_t">Fikrle T, Pizinger K. [The use of the 308 nm excimer laser for the treatment of psoriasis]. J Dtsch Dermatol Ges 2003; 1:559.</a></li><li><a class="nounderline abstract_t">Feldman SR, Mellen BG, Housman TS, et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol 2002; 46:900.</a></li></ol></div><div id="topicVersionRevision">Topic 13752 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15656808" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25606333" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 308nm excimer laser in dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25606333" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 308nm excimer laser in dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16149939" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Phototherapy: how does UV work?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17342112" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cracking the cytokine code in psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12007465" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12834450" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Monochromatic excimer light (308 nm): an immunohistochemical study of cutaneous T cells and apoptosis-related molecules in psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25822579" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Narrow Band Ultraviolet B Treatment for Human Vitiligo Is Associated with Proliferation, Migration, and Differentiation of Melanocyte Precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846147" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chronic pruritus--pathogenesis, clinical aspects and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16297008" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ultraviolet phototherapy for pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837151" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Using light in dermatology: an update on lasers, ultraviolet phototherapy, and photodynamic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A review of localized office and home devices in the treatment of psoriasis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20178697" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A review of home phototherapy for psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25773416" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Randomized, parallel group trial comparing home-based phototherapy with institution-based 308 excimer lamp for the treatment of focal vitiligo vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11125334" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Recent advances in phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18380207" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24326569" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Excimer laser: a module of the alopecia areata common protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23053247" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Targeted phototherapy using 308 nm Xecl monochromatic excimer laser for psoriasis at difficult to treat sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32749663" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dermoscopic and Clinical Response Predictor Factors in Nonsegmental Vitiligo Treated with Narrowband Ultraviolet B Phototherapy: A Prospective Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10815855" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : 308-nm excimer laser for the treatment of psoriasis: a dose-response study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23748556" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Minimal Erythema Dose (MED) testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22206083" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A review of protocols for 308 nm excimer laser phototherapy in psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19811850" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33047405" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparative efficacy between localized 308-nm excimer light and targeted 311-nm narrowband ultraviolet B phototherapy in vitiligo: A randomized, single-blind comparison study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22515588" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy and safety of non-laser, targeted UVB phototherapy alone and in combination with psoralen gel or calcipotriol ointment in the treatment of localized, chronic, plaque-type psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32419530" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Combination of targeted UVB phototherapy and calcipotriene versus targeted UVB alone in psoriasis: systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24665924" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Short- to intermediate-term follow-up in patients treated with the combination of 311-nm ultraviolet B phototherapy and biological agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25710794" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Interventions for vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7868718" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21429620" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A review of phototherapy protocols for psoriasis treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16295041" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : [The use of the 308 nm excimer laser for the treatment of psoriasis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12063488" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
